Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

petersadick Sep. 15 at 7:54 PM

$SNSE this is whar happens when the feds raise interest rates. raising rates, all prices will go up creating higher inflation and stock market frops

0 · Reply

MingChoo Sep. 13 at 10:16 PM

$SNSE Looking for green12

0 · Reply

petersadick Sep. 9 at 7:55 PM

$SNSE love it another day like today and i can buy more, or are we headed down to 24.00 like the last time we hit a new high?

0 · Reply

Floridaorange Sep. 8 at 3:40 PM

$SNSE NGEN next 💪🇨🇦🇺🇸

0 · Reply

Jausman Aug. 26 at 3:37 PM

$SNSE Seems this is still THE stock twits board of preferences- for - the usual pumpers, fudsters, fans , bots and former meme investors - Also, you contributors that are serious about the steps that the company is taking to assure a future profit …~the press releases, filings, approvals, offerings, loans ..a lot. . Someone on the AXSM board suggested I look at this for a similar, share appreciation story (TY to them) /// And why dont any of you post on FTH ? Just wonder. :)

0 · Reply

Howegainz Aug. 10 at 4:11 PM

$SNSE what a recovery!

0 · Reply

petersadick Jul. 16 at 8:56 PM

$SNSE down 10.00? did the cfo sell out his shares that he just bought at 23.31 for 36.00? no reason for this drop other than a crooked market

0 · Reply

petersadick Jul. 15 at 6:36 PM

$SNSE dang this is going the wrong way, the ceo needs to buy more to prop upp the price again

0 · Reply

FilingTracker Jun. 24 at 10:59 PM

$SNSE -> $FTH CFO purchased additional shares: https://filingtracker.ai/filing/1780030/0001780030-26-000004

0 · Reply

BearTamerTradingLLC Jun. 24 at 6:22 PM

$GPUS $SKYQ $RCT $SNSE I don’t just alert, signal, and educate. I put my money where my alert is 😇, Part 1 of 4 Don’t forget to grab your celebration pass or BTT membership. Opportunities are here daily. Congratulations members. https://www.youtube.com/channel/UCfsmfz5F8NRG4H70oOK1CNA/join

1 · Reply

Faeth Therapeutics initiated with a Buy at Guggenheim

2026-09-14T14:55:22.000Z - 1 day ago

Faeth Therapeutics assumed with a Buy at Lucid Capital

2026-09-09T10:10:57.000Z - 6 days ago

Faeth Therapeutics initiated with a Buy at TD Cowen

Sep 8, 2026, 7:30 AM EDT - 7 days ago

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

Sep 1, 2026, 7:30 AM EDT - 14 days ago

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

Aug 28, 2026, 7:30 AM EDT - 18 days ago

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-21T10:05:19.000Z - 25 days ago

Faeth Therapeutics initiated with a Buy at Needham

2026-08-17T11:35:53.000Z - 4 weeks ago

Faeth Therapeutics granted Fast Track desingation for PIKTOR plus Paclitaxel

Aug 17, 2026, 7:30 AM EDT - 4 weeks ago

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

2026-08-16T13:36:21.000Z - 4 weeks ago

Faeth Therapeutics appoints Tiwari, Biegler as Senior Vice Presidents

Aug 14, 2026, 7:30 AM EDT - 4 weeks ago

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

Aug 7, 2026, 7:30 AM EDT - 5 weeks ago

Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference

2026-08-04T16:25:41.000Z - 6 weeks ago

Faeth Therapeutics management to meet with BTIG

2026-08-04T12:01:21.000Z - 6 weeks ago

Faeth Therapeutics initiated with a Buy at JonesResearch

2026-08-04T11:36:09.000Z - 6 weeks ago

Faeth Therapeutics reports Q2 EPS ($2.84) vs ($3.91) last year

Aug 4, 2026, 7:30 AM EDT - 6 weeks ago

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

2026-07-31T10:10:24.000Z - 6 weeks ago

Faeth Therapeutics initiated with an Outperform at Raymond James

2026-07-27T20:30:09.000Z - 7 weeks ago

Faeth Therapeutics initiated with an Outperform at Oppenheimer

2026-07-20T08:40:05.000Z - 1 month ago

Faeth Therapeutics initiated with an Outperform at Citizens

2026-07-15T19:45:27.000Z - 2 months ago

Faeth Therapeutics, Inc trading resumes

2026-07-15T19:35:29.000Z - 2 months ago

Faeth Therapeutics, Inc trading halted, volatility trading pause

2026-06-25T20:21:04.000Z - 2 months ago

Faeth Therapeutics initiated with an Outperform at Baird

2026-06-22T10:09:32.000Z - 2 months ago

Faeth Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-18T20:05:40.000Z - 2 months ago

Faeth Therapeutics files automatic mixed securities shelf

Jun 15, 2026, 8:10 AM EDT - 3 months ago

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

Jun 4, 2026, 4:00 PM EDT - 3 months ago

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

Apr 9, 2026, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 30, 2026, 7:30 AM EDT - 5 months ago

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 18, 2026, 8:00 AM EST - 6 months ago

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Jan 7, 2026, 8:00 AM EST - 8 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Nov 14, 2025, 7:30 AM EST - 10 months ago

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 9:00 AM EDT - 10 months ago

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

Oct 17, 2025, 8:00 AM EDT - 11 months ago

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

Sep 23, 2025, 7:30 AM EDT - 11 months ago

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 1 year ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 2 years ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 2 years ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 2 years ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

petersadick Sep. 15 at 7:54 PM

$SNSE this is whar happens when the feds raise interest rates. raising rates, all prices will go up creating higher inflation and stock market frops

0 · Reply

MingChoo Sep. 13 at 10:16 PM

$SNSE Looking for green12

0 · Reply

petersadick Sep. 9 at 7:55 PM

$SNSE love it another day like today and i can buy more, or are we headed down to 24.00 like the last time we hit a new high?

0 · Reply

Floridaorange Sep. 8 at 3:40 PM

$SNSE NGEN next 💪🇨🇦🇺🇸

0 · Reply

Jausman Aug. 26 at 3:37 PM

0 · Reply

Howegainz Aug. 10 at 4:11 PM

$SNSE what a recovery!

0 · Reply

petersadick Jul. 16 at 8:56 PM

$SNSE down 10.00? did the cfo sell out his shares that he just bought at 23.31 for 36.00? no reason for this drop other than a crooked market

0 · Reply

petersadick Jul. 15 at 6:36 PM

$SNSE dang this is going the wrong way, the ceo needs to buy more to prop upp the price again

0 · Reply

FilingTracker Jun. 24 at 10:59 PM

$SNSE -> $FTH CFO purchased additional shares: https://filingtracker.ai/filing/1780030/0001780030-26-000004

0 · Reply

BearTamerTradingLLC Jun. 24 at 6:22 PM

1 · Reply

Bretm50 Jun. 24 at 4:31 PM

$SNSE Up 92% in a week, whats not to like? Room for further gains!

0 · Reply

BearTamerTradingLLC Jun. 23 at 5:27 PM

$SNSE Another potential rocket video released last week generating profit opportunities for members. An immediate return on investments 🔥 https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

0 · Reply

BearTamerTradingLLC Jun. 23 at 5:26 PM

$SNSE https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

0 · Reply

BearTamerTradingLLC Jun. 23 at 5:25 PM

$SNSE Another potential rocket video released last week generating profit opportunities for members. https://www.youtube.com/live/RvTR5F1VW6w?is=TErIfu946iBF3V3g

1 · Reply

Stallions Jun. 23 at 2:22 PM

$SNSE Ready for Epic run

0 · Reply

YorkMeister Jun. 22 at 9:46 PM

$SNSE 55-60$ recent analyst price target

0 · Reply

aswadhama Jun. 22 at 8:29 PM

$SNSE ,I entered this one at $28.00 .I am relieved with the run today. Hoping to get break even soon and will get out of it.

0 · Reply

Stallions Jun. 22 at 7:47 PM

$SNSE Extremely Bullish. Solid phase 2 data expected. $200M cash in hand. This is going to be an EPIC stock

0 · Reply

Zardiw Jun. 22 at 1:06 PM

$NWBO - #DDAmanda Chart. Showing up on the scanner. Also flagged: $AKAN $CUPR $SNSE More charts at: https://DDAmanda.com

1 · Reply

BearTamerTradingLLC Jun. 20 at 5:19 AM

$SNSE Free Potential Rocket alert !🚨 $FTH https://www.youtube.com/live/RvTR5F1VW6w?is=Z83h4q3m8ahd9Ge5

0 · Reply

Stallions Jun. 17 at 7:33 PM

$SNSE Huge potential! This drug will be a breakthrough and will achieve new milestone in cancer treatment space. Have little more patience for phase 2 readout

0 · Reply

jrw06 Jun. 17 at 6:08 PM

$SNSE why is this board so quiet?

0 · Reply

Market Cap	18.59M
Revenue (ttm)	0.00
Net Income (ttm)	-21.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	219,700
Avg Vol	41,964
Day's Range	N/A - N/A
Shares Out	1.34M
Stochastic %K	39%
Beta	-0.25
Analysts	Strong Sell
Price Target	$52.50